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To the Editor  
Renal denervation has been approved as a standard treatment option for resistant 
hypertension in many countries since 2010. The efficacy of renal denervation in lowering 
blood pressure is controversial [1], emphasizing that more research needs to be conducted to 
investigate the effect of renal denervation on blood pressure. In previous clinical trials on 
renal denervation, blood pressure was mainly monitored by office blood pressure; when 
ambulatory blood pressure data were available, such data were often incomplete because 
ambulatory blood pressure was not designed as the primary efficacy outcome.  
A large amount of evidence suggests that ambulatory blood pressure may be a better 
inclusion criterion, and changes in ambulatory blood pressure may be designed as the primary 
efficacy outcome in clinical trials on renal denervation for the following reasons: 
1. Limitations in office blood pressure measurement 
Office blood pressure measurement is well known to produce a white coat effect. Therefore, 
measurement of office blood pressure, though standard and well-established, is often 
misleading. For example, 37.5% of patients with resistant hypertension based on office blood 
pressure were found to have white coat hypertension [2] which may not contribute to 
cardiovascular events [3]. It has been shown that renal denervation does not lower 
ambulatory blood pressure in subjects with white coat hypertension [4]. Therefore, 
performing renal denervation in subjects with white coat hypertension may raise ethical 
concerns because long-term side effects of renal denervation are unknown [5]. 
In addition, office blood pressure measured at a certain time point of the day may not 
accurately reflect the blood pressure levels in patients with resistant hypertension who take 
≥3 antihypertensive drugs. Office blood pressure can change dramatically after the intake of 
antihypertensive drugs. For example, the office systolic blood pressure in a renal denervated 
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patient decreased from 177 mm Hg at baseline to 97, 94 and 140 mm Hg at 1, 2 and 6 h after 
the intake of antihypertensive drugs, respectively [6]. Therefore, without information on 
when patients take antihypertensive drugs and when blood pressure is measured, office blood 
pressure would have a limited power accurately to assess the effect of renal denervation on 
blood pressure. 
2. The superiority of ambulatory blood pressure monitoring 
Ambulatory blood pressure monitoring is regarded as the gold standard to diagnose true 
hypertension [7]. It removes the white coat effect. Therefore, using ambulatory blood 
pressure as an inclusion criterion is able to ensure that renal denervation will not be 
performed in subjects with white coat hypertension.  
Compared with office blood pressure, ambulatory blood pressure provides better estimates of 
a patient’s cardiovascular prognosis. For example, the Systolic Hypertension in Europe (Syst-
Eur) trial showed that in the placebo group office blood pressure at baseline was only weakly 
associated with cardiovascular events and stoke (P>0.05), whereas the 24-hour ambulatory 
blood pressure significantly predicted fatal and nonfatal cardiovascular events and stoke [8]. 
The 24-hour ambulatory blood pressure still predicted the incidence of fatal and nonfatal 
cardiovascular events and stroke after adjustment for the office blood pressure [8]. 
In addition, ambulatory blood pressure can provide information on drug non-adherence which 
is a major limitation in the current clinical trials on renal denervation [9].  Ambulatory blood 
pressure monitoring provides blood pressure values over a 24-hour period. Therefore, it can 
provide information on drug non-adherence using the pattern of the blood pressure change 
after the intake of antihypertensive drugs in renal denervated patients [6]. This advantage of 
ambulatory blood pressure monitoring has not been explored in clinical trials on renal 
denervation and it is worthwhile to fully utilize this information in the future. 
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In summary, ambulatory blood pressure may be a better inclusion criterion, and changes in 
ambulatory blood pressure may be designed as the primary efficacy outcome in clinical trials 
on renal denervation in the future. 
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